MGLL and Alzheimer disease: It has been shown that both the application of CB1R agonists [25–27] and also the inactivation of the activity of monoacylglycerol lipase (MAGL), the enzyme that hydrolyzes 2-AG, result in an increase of 2-AG levels and restore LTP in a mouse model of AD [28], suggesting critical involvement of the eCB system in hippocampal LTP induction.